OOncostellae
Oncostellae is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule drug candidates for high unmet needs in immunology and oncology, taking assets through Phase I/II and then out-licensing them to pharma partners. Its lead programs are OST-122, a JAK inhibitor for ulcerative colitis (Phase 2a), and OST-499, a glucocorticoid receptor antagonist for colorectal cancer and other solid tumours (Phase 1). Founded in 2013 as a spin-out linked to the University of Santiago de Compostela, it is a small team (~10-19 people) funded by Galician/Spanish venture and public capital plus equity crowdfunding. It is headquartered in Santiago de Compostela (Galicia) with a secondary office at the Barcelona Science Park.
Founders
Global models 5
N
I
A
K
VIn the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 8
Open as list →
I
U
X
C
CFunding rounds 3
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-03-19 | Series A (estimated) | €500K partial: only one investor's ticket was disclosed |
Lead not disclosed
+2 more
|
| 2022-07-04 | Series A (estimated) | €3.3M |
Lead not disclosed
+7 more
|
| 2017-07-23 | Seed (estimated) | €1.85M |
Fundadores de Palobiofarma
+3 more
|